ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/032/SRR10143732/SRR10143732.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/043/SRR10143743/SRR10143743.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/035/SRR10143735/SRR10143735.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/038/SRR10143738/SRR10143738.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/034/SRR10143734/SRR10143734.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/031/SRR10143731/SRR10143731.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/040/SRR10143740/SRR10143740.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/042/SRR10143742/SRR10143742.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/036/SRR10143736/SRR10143736.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/044/SRR10143744/SRR10143744.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/033/SRR10143733/SRR10143733.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/045/SRR10143745/SRR10143745.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/030/SRR10143730/SRR10143730.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/039/SRR10143739/SRR10143739.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/037/SRR10143737/SRR10143737.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR101/041/SRR10143741/SRR10143741.fastq.gzprimaryOK200GenomicsAdam Green, Pediatrics, University of Coloradohttps://www.ebi.ac.uk/ena/browser/view/PRJNA566346Homo sapiensCultured pediatric high-grade glioma cell lines (SU-DIPG-IV, HSJD-DIPG-007, HSJD-GBM-001,BT 245 (RRID:CVCL_IP13)) were treated with selinexor (Karyopharm Therapeutics) at 5xIC50 for 16 hours or vehicle (0.1% DMSO) followed by bulk RNA-Seq Overall design: Examination of the effects on gene expression of selinexor treatment of cultured pediatric brain tumor cell linesxref:PubMed:31594826ENAfalseGene expression (RNA-Seq) in pediatric high-grade glioma cell lines treated with selinexor and vehicleGene expression (RNA-Seq) in pediatric high-grade glioma cell lines treated with selinexor and vehicle2025-09-242020-01-08PRJNA566346GSE137702960631594826